- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05098327
Pioglitazone and Insulin Resistance in ADT
Role of Pioglitazone Therapy in Management of Insulin Resistance Associated With Androgen Deprivation Therapy (ADT) in Patients With Prostate Cancer
Study Overview
Status
Intervention / Treatment
Detailed Description
This is a single-center, cross-sectional then prospective, randomized single-blinded study with 2 groups of subjects. One group will be men with prostate cancer in various stages of ADT and the other group will be men with prostate cancer not on ADT as control group.
Patients interested in participating who meet the inclusion/exclusion criteria and who agree to undergo blood draws and fat biopsy will be identified from the Genito-urinary oncology and urology clinics. These patients will be referred to the Diabetes and Endocrinology Research Center of WNY where they will undergo blood draws in fasting state.
On the screening day, participants will be asked to complete the informed consent, medical history and physical exam, and non-fasting blood draws (for CBC, CMP and HbA1c) prior to participating in the study. 30 ml of blood will be drawn at this visit.
Subjects who qualify and consent to take part in the study will be called in for the baseline study visit where they will undergo blood draws in fasting state. HOMA-IR method will be used to determine insulin resistance. Subcutaneous fat biopsies will be performed in all patients.
Within the ADT group, subjects will be assigned a number by a computerized simple random number generation program (Excel, Microsoft Inc.) and will be randomized (1:1) to receive either pioglitazone or placebo. The patient will be blinded to the treatment, however, the research team will not. Subjects will be given a 12 week supply of pioglitazone 30 mg or placebo pills containing cellulose that will take once a day in morning. Subjects who develop side effects (weight gain, pedal edema) on the 30 mg dose will be asked to reduce the dose to 15 mg.
Subjects will then return to the research center in 12 weeks for visit 2 where the fasting blood draws and subcutaneous fat biopsies will be performed again. The subjects will then be discharged from the study and follow with their physicians. Subject will receive a phone call after 1 and 4 weeks following start of treatment to collect any safety data. Patients will be instructed to call the research center anytime they have a question or side effects.
Study Type
Phase
- Phase 3
Contacts and Locations
Study Contact
- Name: Husam Ghanim, PhD
- Phone Number: 716-881-8924
- Email: ghanim@buffalo.edu
Study Locations
-
-
New York
-
Buffalo, New York, United States, 14221
- Diabetes and Endocrinology Research Center of WNY
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Male, age ≥18 years of age.
- Body Mass Index of > 25 kg/m2
- Biopsy-confirmed prostate adenocarcinoma currently on androgen deprivation therapy (ADT) for minimum of 3 months for the ADT group and biopsy-confirmed prostate adenocarcinoma not on ADT for control group
5. Hemoglobin > 11 g/dL, Creatinine < 1.5x ULN and liver function tests < 2x ULN 6. Participant must be able to read, write, and understand the English language and be able to provide written consent 7. Participant must understand the investigational nature of this study and sign an Independent Ethics Committee/Institutional Review Board approved written informed consent form prior to receiving any study related procedure
Exclusion Criteria:
- Known clinically significant severe COPD, ischemic heart disease, congestive heart failure, and/or significant cardiac arrhythmias
- Any patient with known diabetes (A1c > 6.4%) or an anti-diabetic drug
- Any condition contraindicating additional blood collection beyond standard of care
- Subjects with known allergy to lidocaine (this is used to anesthetize area for fat biopsy)
- Subjects with known allergy to pioglitazone or other thiazolidinediones
- Subjects with pioglitazone use in last 6 months
- Subjects with congestive Heart Failure Class 3 or 4
- Subjects with osteoporosis, including history of fragility fracture
- Subjects with history of bladder cancer
- Subjects on chronic use of androgens, or opiates in the last 6 months or with panhypopituitarism, congenital HH (hypogonadotropic hypogonadism), prolactinoma, head trauma
- Unwilling or unable to follow protocol requirements
- Any condition which in the Investigator's opinion deems the participant an unsuitable candidate to undergo study procedures.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Prostate cancer on ADT receiving pioglitazone
Subjects will receive a 12-week supply of pioglitazone 30 mg dose 1 tab daily
|
pioglitazone 30 mg dose 1 tab daily will be given for 12 weeks
Other Names:
|
Placebo Comparator: Prostate cancer on ADT receiving placebo
Subjects will receive a 12 week supply of placebo pills containing cellulose
|
placebo pills containing cellulose 1 pill daily will be given for 12 weeks
|
No Intervention: Prostate cancer not on ADT
No intervention will be done in this group
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
HOMA-IR
Time Frame: 12 weeks
|
Change in HOMA-IR (the main index for evaluating insulin resistance) following pioglitazone and placebo treatment.
|
12 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
IRS-1 serine phosphorylation
Time Frame: 12 weeks
|
Determine levels of IRS-1 serine phosphorylation in adipose tissue and MNC as a molecular marker of inflammation induced insulin resistance at baseline and after pioglitazone and placebo treatments
|
12 weeks
|
IRβ
Time Frame: 12 weeks
|
Changes in expression of insulin signaling gene (IRβ) in both adipose tissue and MNC between the ADT and non-ADT groups at baseline and after pioglitazone and placebo treatments in ADT group
|
12 weeks
|
IRS-1
Time Frame: 12 weeks
|
Changes in expression of insulin signaling gene (IRS-1) in both adipose tissue and MNC between the ADT and non-ADT groups at baseline and after pioglitazone and placebo treatments in ADT group
|
12 weeks
|
AKT-2
Time Frame: 12 weeks
|
Changes in expression of insulin signaling gene (AKT-2) in both adipose tissue and MNC between the ADT and non-ADT groups at baseline and after pioglitazone and placebo treatments in ADT group
|
12 weeks
|
GLUT-4
Time Frame: 12 weeks
|
Changes in expression of GLUT-4 in adipose tissue between the ADT and non-ADT groups at baseline and after pioglitazone and placebo treatments in ADT group
|
12 weeks
|
TNF-α
Time Frame: 12 weeks
|
Changes in expression of proinflammatory gene (TNF-α) that interfere with insulin signaling transduction in adipose tissue and MNC between the ADT and non-ADT groups at baseline and after pioglitazone and placebo treatments in ADT group
|
12 weeks
|
IL 1β
Time Frame: 12 weeks
|
Changes in expression of proinflammatory gene (IL 1β) that interfere with insulin signaling transduction in adipose tissue and MNC between the ADT and non-ADT groups at baseline and after pioglitazone and placebo treatments in ADT group
|
12 weeks
|
IKK-β
Time Frame: 12 weeks
|
Changes in expression of proinflammatory gene (IKK-β) that interfere with insulin signaling transduction in adipose tissue and MNC between the ADT and non-ADT groups at baseline and after pioglitazone and placebo treatments in ADT group
|
12 weeks
|
SOCS-3
Time Frame: 12 weeks
|
Changes in expression of proinflammatory gene (SOCS-3) that interfere with insulin signaling transduction in adipose tissue and MNC between the ADT and non-ADT groups at baseline and after pioglitazone and placebo treatments in ADT group
|
12 weeks
|
PTB-1B
Time Frame: 12 weeks
|
Changes in expression of proinflammatory gene (PTB-1B) that interfere with insulin signaling transduction in adipose tissue and MNC between the ADT and non-ADT groups at baseline and after pioglitazone and placebo treatments in ADT group
|
12 weeks
|
JNK-1
Time Frame: 12 weeks
|
Changes in expression of proinflammatory gene (JNK-1) that interfere with insulin signaling transduction in adipose tissue and MNC between the ADT and non-ADT groups at baseline and after pioglitazone and placebo treatments in ADT group
|
12 weeks
|
TLR-4
Time Frame: 12 weeks
|
Changes in expression of proinflammatory gene (TLR-4) that interfere with insulin signaling transduction in adipose tissue and MNC between the ADT and non-ADT groups at baseline and after pioglitazone and placebo treatments in ADT group
|
12 weeks
|
Collaborators and Investigators
Investigators
- Principal Investigator: Paresh Dandona, MD, PhD, SUNY at Buffalo
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Glucose Metabolism Disorders
- Metabolic Diseases
- Neoplasms
- Urogenital Neoplasms
- Neoplasms by Site
- Endocrine System Diseases
- Diabetes Mellitus
- Genital Neoplasms, Male
- Prostatic Diseases
- Hyperinsulinism
- Urogenital Diseases
- Male Urogenital Diseases
- Genital Diseases, Male
- Genital Diseases
- Diabetes Mellitus, Type 2
- Prostatic Neoplasms
- Insulin Resistance
- Hypoglycemic Agents
- Physiological Effects of Drugs
- Pioglitazone
Other Study ID Numbers
- STUDY00005310
- UL1TR001412 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabetes Mellitus, Type 2
-
SanofiCompletedType 1 Diabetes Mellitus-Type 2 Diabetes MellitusHungary, Russian Federation, Germany, Poland, Japan, United States, Finland
-
Mannkind CorporationTerminatedType 2 Diabetes Mellitus | Type 1 Diabetes MellitusUnited States
-
RWTH Aachen UniversityBoehringer IngelheimCompletedDiabetes Mellitus Type 2 (T2DM)Germany
-
Scripps Whittier Diabetes InstituteSan Diego State UniversityCompletedType 2 Diabetes Mellitus (T2DM)United States
-
University Hospital Inselspital, BerneCompletedType 2 Diabetes MellitusSwitzerland
-
India Diabetes Research Foundation & Dr. A. Ramachandran...CompletedTYpe 2 Diabetes MellitusIndia
-
US Department of Veterans AffairsAmerican Diabetes AssociationCompletedType 2 Diabetes MellitusUnited States
-
Dexa Medica GroupCompletedType-2 Diabetes MellitusIndonesia
-
Griffin HospitalCalifornia Walnut CommissionCompletedDIABETES MELLITUS TYPE 2United States
-
Diabetes Foundation, IndiaNational Diabetes Obesity and Cholesterol FoundationRecruitingType 2 Diabetes Mellitus With ComplicationIndia
Clinical Trials on Pioglitazone 30 mg
-
West Virginia UniversityRecruitingBreast Cancer | Muscle FatigueUnited States
-
Johns Hopkins UniversityActive, not recruiting
-
Boehringer IngelheimCompletedDiabetes Mellitus, Type 2United States, Argentina, Austria, Belgium, Canada, China, Croatia, Czech Republic, Finland, Germany, Greece, Hungary, India, Israel, Italy, Japan, Korea, Republic of, Malaysia, Mexico, Netherlands, New Zealand, Philippines, Poland, R... and more
-
Boehringer IngelheimEli Lilly and CompanyCompletedDiabetes Mellitus, Type 2United States, Estonia, Germany, Latvia, Spain, United Kingdom
-
Johnson & Johnson Pharmaceutical Research & Development...CompletedDiabetes Mellitus, Type 2
-
Fundacion para la Investigacion Biomedica del Hospital...Completed
-
Merck Sharp & Dohme LLCCompletedNon-alcoholic Fatty Liver Disease
-
St. Louis UniversityWithdrawnInsulin Resistance | Prostate CancerUnited States
-
St. Louis UniversityWithdrawn
-
Boehringer IngelheimCompletedDiabetes Mellitus, Type 2Austria, Greece, Hungary, Japan, Portugal, Romania, Spain